Ann: US patent issued for DEP cabazitaxel nanoparticle, page-29

First 29 Last

Share
Profile

Follow
Domesticgod

1,790 Posts.

317

15/09/21

21:03

Post #: 56096513
Share

Originally posted by chrisnj ↑

Well done Domesticgod for finding this interesting document.

This shows that our scientists have been recently conducting experiments on rabbit eyes with a degree of success which has lead to their conclusion that further development would be a good idea.

Well it's only taken 8 years to reach this point.

This is a classic demonstration of the shareholders being kept in a void and given absolutely no indication of the activity in their laboratories. Of course we do not expect a blow by blow account but we are told there's a huge market opportunity and we're in commercial discussions in 2013 only to find out courtesy of some good diligence from Domesticgod that further development would be a smart move in 2021 after what l conclude to be recent studies.

Any comments from the more scientifically savvy members of HC would be welcome on this study.

Expand

Just in case anyone thinks the conjunctivitis study conclusions were a one off, then read this study from August 21

www.mdpi.com/1999-4915/13/8/1656/htm

Protective Effects of Astodrimer Sodium 1% Nasal Spray Formulation against SARS-CoV-2 Nasal Challenge in K18-hACE2 Mice

In it, Jeremy Paul et all conclude that:-

“The potential protective effects of astodrimer sodium 1% nasal spray warrant further investigation to help combat SARS-CoV-2 infection in humans.”

Not “immediate commercialisation”, but “further investigation ”.
How much more investigation? A month? A year?? Five years???

SPL Price at posting: $1.37 Sentiment: Hold Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

PL3

Patagonia looks to raise $2.15M for South American exploration and development

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

SPR

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

There are more pages in this discussion • 13 more messages in this thread...

First 29 Last

Add SPL (ASX) to my watchlist

(20min delay)
Last 9.7¢		Change 0.000(0.00%)		Mkt cap ! $40.00M

Open	High	Low	Value	Volume
9.8¢	10.5¢	9.6¢	$210.8K	2.098M

Buyers (Bids)

No.	Vol.	Price($)
1	30408	9.5¢

Sellers (Offers)

Price($)	Vol.	No.
9.7¢	3523	2

View Market Depth

No.	Vol.	Price($)
1	30408	0.095
2	15638	0.094
3	83394	0.093
2	108435	0.091
2	41000	0.090

Price($)	Vol.	No.
0.097	3523	2
0.105	119848	4
0.110	114099	6
0.115	77331	6
0.120	89055	5

Last trade - 16.10pm 09/07/2024 (20 minute delay)

SPL (ASX) Chart

Ann: US patent issued for DEP cabazitaxel nanoparticle, page-29

Patagonia looks to raise $2.15M for South American exploration and development

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: US patent issued for DEP cabazitaxel nanoparticle, page-29

Top Stories

Patagonia looks to raise $2.15M for South American exploration and development

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News